옵투스제약

131030KOSDAQ의약품 제조업

54.5 / 100

Reference Date: 2026-04-13

Financial Score26.0 / 40

News Sentiment12.5 / 25

Momentum6.0 / 20

Disclosure10.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health but Operating Profit metrics are weak. Declined 5.9% over the past month, and news sentiment is neutral.

Company InformationBased on 2025 Annual Report

Business Overview

Optus Pharma specializes in developing and producing ophthalmic treatments for conditions such as dry eye and glaucoma, establishing a strong presence in the domestic market with products like Tierlin Pi eye drops. The company plans to expand its annual production capacity of single-use eye drops to 830 million units by 2026 with a new factory, while also growing its CMO/CDMO and global business segments to expand internationally.

Number of Employees

250people

Average Salary

54.2M KRW

Score Calculation Basis

Detailed Financial Score

PER

13.68Industry Average 14.805.0Point

In line with industry avg

PBR

1.07Industry Average 1.042.5Point

Higher than industry avg (caution)

ROE

7.36Industry Average 4.425.5Point

1.7x industry avg (good)

Debt Ratio

0.27Industry Average 11.988.0Point

Half of industry avg (excellent)

Trend 2023~20255.0 / 10 points

Revenue Growth Rate

2.0 / 3

Avg ▲9.8% (2-year basis)

Operating Profit Growth Rate

1.0 / 3

Avg ▲4.1% (2-year basis)

ROE Trend

2.0 / 4

Avg ROE 7.7% (declining, 3yr)

Detailed News Sentiment

3 totalPositive 0Neutral 0Negative 0

Detailed Momentum

52-week position3.0Point

52w lower range (29%)

Current 10,000Won52-week high 19,26052-week low 6,040

1-month return2.0Point

1m -5.93% (slight drop)

Volume trend1.0Point

Volume decreasing

Detailed Disclosure

4 totalPositive 0Neutral 4Negative 0

Neutral주요사항보고서(자기주식처분결정)2026-03-26
Neutral정기주주총회결과2026-03-25
Neutral사외이사의선임ㆍ해임또는중도퇴임에관한신고2026-03-25
Neutral사업보고서 (2025.12)2026-03-17